Citations 1
Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC).
Ciombor, Kristen K. , Farhat, Mohamed, Kirshner, Jeffrey J., Knost, James A., Anderson, Daniel M. , Soori, Gamini S. , Wender, Donald B., Desnoyers, Rodwige J., Bekaii‐Saab, Tanios , Ou, Fang‐Shu , Boland, Patrick M. , Sargent, Daniel J. , Grothey, Axel
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS3630-TPS3630
